うつ病における孤独
うつ病治療における孤独感の影響
この前向き研究の目的は、うつ病の入院精神科治療における孤独とうつ病の関連性をより深く理解することです。 以下の問いに答えることを目指します:
孤独な人と孤独でない人は、入院うつ病治療から同じように恩恵を受けるでしょうか? 孤独はうつ病の入院治療において臨床的に重要な因子でしょうか? 基礎となる生物心理社会的メカニズムは何でしょうか?
参加者は以下のことを行うよう求められます
- 自己記入式質問票
- 臨床面接
- 3つの主要な測定時点(1. 入院治療開始時、2. 退院日、3. 退院後3ヶ月)での生体サンプリング(血液、唾液、便)
調査の概要
詳細な説明
孤独と抑うつは広く蔓延し、深刻な健康障害をもたらす状態です。 特に、孤独と抑うつは密接に関連しており、抑うつに苦しむ個人は孤独に対して特に脆弱です。 しかし、抑うつの治療における孤独の臨床的意義と、この関連の根底にある生物心理社会的メカニズムについては、ほとんど知られていません。
孤独と抑うつの相互作用の臨床的関連性を調査するために、前向きで非介入的な縦断的デザインが採用されます。 この研究は、ドイツのエアランゲンにある大学病院と地域病院で実施されます。 抑うつ症状で入院したすべての患者は、組み入れ基準と除外基準に従ってスクリーニングの対象となります。 3つの主要な測定時点(T0、T1、T2)と、2週間間隔で行われる簡易な中間測定(t0.1からt0.Xおよびt1.1からt1.6)が利用されます。 スクリーニングと臨床面接の後、参加者はベースライン測定(T0)を完了します。 その後、各参加者は、その特定の患者の入院期間に対応する個別の期間を遵守し、2回目の測定(T1)が得られるまで継続します。 追跡調査はT1の3か月後に行われます。
臨床集団における孤独と抑うつの相互作用の効果量は現在不明であるため、この研究のサンプルサイズは、実現可能性、得られた結果の集団一般化可能性、および統計的妥当性に基づいて決定されました。
結果の外的妥当性を確保するためには、重度に孤独な抑うつ患者とあまり孤独でない抑うつ患者、および異なる疾患経過と患者特性(例:年齢、性別、併存疾患数)を特定できることが重要です。 約200人の参加者のサンプルサイズは、十分な異質性を確保すると期待されます。 このサンプルサイズは実現可能です。なぜなら、エアランゲンの大学病院と地域病院における抑うつの一次診断の組み入れ率を50%、脱落率を30%と仮定しても、推定2年間の期間内に募集可能数が目標症例数を明らかに上回るからです。
ベースラインで測定された孤独のどのレベルが強い孤独を表し、どのレベルが抑うつ患者集団における弱い孤独を表すかについての知識がないため、ベースラインでの孤独の中央値分割が行われ、入院中および追跡経過(T0、T1、T2)における孤独と抑うつの相互作用の統計的有意性が計算されます。 混合分散分析(ANOVA)の有意な交互作用効果を検出するために、αエラーを0.05、検出力を0.9(1-βエラー確率)、反復測定間の相関係数を高度に孤独な群とわずかに孤独な群として定義された群に対して0.5と考慮し、G*Powerバージョン3.1.9.7を使用して症例数が計算されました。 小さい効果量(f=0.10)を仮定すると、望ましいサンプルサイズはn=214人と決定されます。さらに、中程度の効果量(f=0.25)を仮定すると、サンプルサイズはn=36人となります。 これは、目標症例数で孤独と抑うつの間の交互作用効果を検出する統計的妥当性があることを示しています。
適格性スクリーニングと臨床診断スクリーニング、および面接は、研究医師によって実施されます。 抑うつは、臨床面接(MADRS)中に患者の治療チームによって評価され、患者の退院時期も決定されます。 すべての自己報告評価は、患者自身がREDCapオンライン調査アプリケーションを使用して収集します。 生物学的サンプリングは、方法論的一貫性と迅速な処理を確保するために、大学病院で募集された参加者の間でのみ行われます。 通常の臨床データは、主に臨床文書システムから抽出され、分析前に統合されます(他のデータソースと同様)。
研究デザインは効果の方向性に関する確定的な因果関係の結論を導くことを許可しないため、知見は貴重な洞察と関連する示唆を提供することが期待されます。 特に、以下の洞察が得られます:(1)より孤独な患者とあまり孤独でない患者が入院中の多面的抑うつ治療から同等の利益を得るかどうかに関する報告;(2)抑うつ治療中および治療後の孤独の変化に関する洞察;(3)孤独と抑うつの根底にある共有および非共有の生物心理社会的メカニズムに関する重要な知見;および(4)生活の質と自殺傾向を含む二次的アウトカムに関する孤独と抑うつの効果。
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Franziska Sonnauer, Dr. med., M.Sc.
- 電話番号:00499131-8534597
- メール:franziska.sonnauer@uk-erlangen.de
研究連絡先のバックアップ
- 名前:Franca Fries, Dr. med.
- 電話番号:004991317530
- メール:Franca.Fries@bezirkskliniken-mfr.de
研究場所
-
-
Bavaria
-
Erlangen、Bavaria、ドイツ、91054
- 募集
- Friedrich-Alexander-Universität Erlangen-Nürnberg
-
コンタクト:
- Franziska Sonnauer, Dr. med.
- 電話番号:00499131-8534597
- メール:einsamkeit-depression.ps@uk-erlangen.de
-
主任研究者:
- Franziska Sonnauer, Dr. med.
-
副調査官:
- Johannes Kornhuber, Prof. Dr. med.
-
副調査官:
- Daniel Blasko, Dr. med.
-
副調査官:
- Ilka Scheer
-
Erlangen、Bavaria、ドイツ、91056
- まだ募集していません
- Bezirkskliniken Mittelfranken, Clinic for Psychiatry, Addiction, Psychotherapie and Psychosomatic Medicine
-
コンタクト:
- Franca Laura Fries, Dr. med.
- 電話番号:004991317535353
- メール:Franca.Fries@bezirkskliniken-mfr.de
-
コンタクト:
- Maksym Druzenko
- 電話番号:004991317535353
- メール:Maksym.Druzenko@bezirkskliniken-mfr.de
-
主任研究者:
- Franca Laura Fries, Dr. med.
-
副調査官:
- Maksym Druzenko
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
組み入れ基準:
- ICD-10(F32またはF33)に基づくうつ病の一次診断(医師または臨床心理学者がM.I.N.I. ミニ国際神経精神診断面接診断ツールと併用して診断)
- 2つの精神科クリニックのいずれかへの入院(予定または緊急入院)
- 18歳以上
- ドイツ語の口頭および文書による十分な理解力
- インフォームド・ボランタリー・コンセント(自発的な同意)
除外基準:
- 現在の同意能力の欠如(例:顕著な精神病症状、昏迷性うつ病症候群、自殺念慮への思考狭窄)
- 過去の本試験への参加
- 妊娠中または授乳中
- 入院期間が7日未満(初期に組み入れ基準を満たしていた場合でも)
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Depression (symptom severity)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Montgomery-Åsberg Depression Rating Scale (MADRS) (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Loneliness
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
3 Item UCLA Loneliness Scale (3-Item UCLA) (3 items, each item rated 1-3 points, minimum 3 points, maximum 9 points, higher scores indicate greater loneliness)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Depression
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Patient Health Questionnaire, 9-Item Depression Scale (PHQ-9) (9 Items, each item rated 0-4 points, minimum 0 points, maximum 27 points, higher scores indicate greater severity of depression)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Loneliness
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
6-Item short scales for Loneliness, De Jong Gierveld Loneliness Scale (6-Item DJGLS) (6 Items, each item rated 1-3 points, before the total score is calculated, the items are dichotomized, thus resulting in a sum score ranging from 0 to 6, wherein scores of 0-1 indicate no loneliness, 2-4 indicate moderate loneliness, and 5-6 indicate severe loneliness)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Social Support
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Fragebogen zur Sozialen Unterstützung (F-SoZ-U 14) (14 Item shortend form, each item rated 0-4 points, minimum 0 points, maximum 56 points, higher total scores indicating higher levels of perceived social support)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Inpatient treatment duration
時間枠:Baseline/T0 (day 1 of inpatient stay) to T1 (end of inpatient stay, normally 7 up to 50 weeks).
|
in days
|
Baseline/T0 (day 1 of inpatient stay) to T1 (end of inpatient stay, normally 7 up to 50 weeks).
|
|
Quality of life in self-report
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
World Health Organization-Five Well-Being Index (WHO-5) (5 Items, each item rated 0-5 points, minimum 0 points, maximum 25 points, the total score (0-25) is transformed to a scale ranging from 0 to 100, with scores ≤50 indicating diminished well-being and higher scores representing higher well-beeing)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Social Network measure (newly designed for this study)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
As there is no culture and language adapted version of a social network indice available an adapted and German-translated version is used to capture participants' social interaction partners during the prior two weeks. The questionnaire was newly developed, with item content informed by existing validated scales (Cohen Social Network Index (SNI), Lubben Social Network Scale (LSNS), Berkman - Social Network/Integration). Via the use of a yes/no response format, participants indicated whether they had personal or telephone contact with each of the following: (1) spouse or partner, (2) own children, (3) parents or parent-like figures, (4) other relatives (e.g., siblings, uncles, or aunts), (5) friends, (6) neighbors, (7) colleagues, (8) people known through voluntary activities, (9) in-laws (parents, sons, or daughters-in-law), and (10) members of their social group (e.g., community, congregation, sports, or music clubs). Higher total scores indicate greater social connectedness. |
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
General health status
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Short Form 12 Health Survey (SF-12) (12 Items, Items rated 0-1, 1-3 and 1-5 and 1-6 scores represent eight dimensions of physical and mental well-beeing with two composite scores, items are recodet, z-transformed and normed, higher values indicate better health)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Social Anxiety
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Social Phobia Inventory (SPIN) (17 Items, each item rated 0-4 points, minimum 0 points, maximum 68 points, higher scores indicate greater severity of social anxiety, three subscales are available (fear 6 items, avoidance 7 items, physiological distress 4 items))
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Somatic Symptom Burden
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
13-Item Somatic Symptom Severity Scale of the Patient Health Questionnaire (PHQ-13) (13 Items, each item rated 0-2 points, minimum 0 points, maximum 34 points, higher values indicating more somatic symptoms)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Blood markers (metabolic, LDL)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
LDL cholesterin [mg/dl or mmol/l], higher values (> 100 mg/dl or > 2.6 mmol/l) represent unfavorable metabolic risk
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (metabolic, HDL)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
HDL cholesterin [mg/dl or mmol/l), < 40 mg/dl men and < 50 mg/dl women represents unfavorable metabolic risk, ≥ 40 mg/dl men ≥ 50 mg/dl women acceptable, ≥ 60 mg/dl protective
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (metabolic, HbA1c)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
HbA1c [%], higher values (> 5.7%) represent unfavorable metabolic risk
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (Sphingolipid metabolism)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Sphingolipid metabolism enzyme activity of secretory acid sphingomyelinase (S-ASM) [nmol/mL/h/µL], higher leveles represent more inflammation/apoptosis enzyme activity of neutral acid sphingomyelinase (N-ASM) [nmol/mL/h/µL], higher levels represent cellular stress/apotosis Ceramide [nmol/L], higher levels represent more inflammation/apoptosis
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (neutrotrophic factor, BDNF)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
brain-derived neurotrophic factor [ng/mL], higher levels represent more neuroplasticity
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (hormonal)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Cortisol [µg/dL or nmol/L] and timepoint of blood test higher levels represent more stress response
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (immunological markers)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
C-reactive protein (CRP) [mg/L], higher levels show systemic inflammation
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Saliva marker (cortisol)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
saliva cortisol (awakening and before bedtime), higher levels represent more stress response
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Saliva marker (α-amylase)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
saliva α-amylase activity [U/ml] (awakening and before bedtime), higher levels represent more stress response
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Stool markers
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
alpha-diversity
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Suicidality (clinician rated)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
measures in clinical interview (Montgomery-Åsberg Depression Rating Scale (MADRS)) (Item No. 10 out of 10 items, rated 0-6, higher values represent more suicidality)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Suicidality (self-report)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
9-Item Patient Health Questionnaire (PHQ-9) (Item No. 9 out of 9, rated 0-3 with higher scores indicating more suicidality)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Response (depression)
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7) to T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks).
|
≥ 50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score from T0 to T1 (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7) to T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks).
|
|
Relapse (depression)
時間枠:T1 (end of inpatient stay/discharge from clinic ± 7 d) to Follow-Up/T2 (three months after clinical discharge ± 7 d).
|
≥ 10 points more from T1 to T2 in Montgomery-Åsberg Depression Rating Scale (MADRS) score or ≥ 22 points at T2 (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)
|
T1 (end of inpatient stay/discharge from clinic ± 7 d) to Follow-Up/T2 (three months after clinical discharge ± 7 d).
|
|
Antidepressant medication
時間枠:Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2), T1 (end of inpatient stay, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
consideration of these classes of antidepressant drugs if these are given in a dosage that is effective as an antidepressant (e.g. for Mirtazapin not 7.5 mg, starting from 15 mg): SSRI/SNRI/NaSSA(Mirtazapin)/NDRI (Buproprion)/TZA/MAO-I/SARI (Trazodon)Agomelatin/other with classes of augmentation strategy: Lithium/antipsychotics/second antidepressant/other augmentation strategy sorted as: antidepressant monotherapy/antidepressant augmented therapy/other and change in therapy stategy (1.
no; 2. yes drug substance (2.1) added/ (2.2) changed/ (2.3) removed; 3. yes dosage of antidepressant changed (3.1) increased/(3.2) decreased; 4. augmentation strategy changed)
|
Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2), T1 (end of inpatient stay, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
trait vs. state loneliness
時間枠:Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Given the absence of an established measure capable of differentiating between enduring (trait) and situational (state) loneliness, this aspect is captured by using a newly developed single item: 'In looking back upon my life, I would say that I have felt …'.
Participants respond to this item on a four-point scale (1= mostly lonely throughout my life, 2= lonely from time to time, 3= only lonely at present, and 4= never lonely).
Responses of 1 are intended to represent trait loneliness; options 2 and 3 represent state loneliness; and option 4 indicates no loneliness.
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
number of therapies participated
時間枠:Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2) to T1 (end of inpatient stay, normally 7 days up to 50 weeks).
|
frequency per week of psychotherapy, group interventions and other
|
Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2) to T1 (end of inpatient stay, normally 7 days up to 50 weeks).
|
協力者と研究者
捜査官
- 主任研究者:Franziska Sonnauer, Dr. med., M.Sc.、Department of Psychiatry and Psychotherapy, Friedrich-Alexander Universität Erlangen-Nürnberg
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。